Cargando…
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
Tebotelimab, a bispecific PD-1×LAG-3 DART molecule that blocks both PD-1 and LAG-3, was investigated for clinical safety and activity in a phase 1 dose-escalation and cohort-expansion clinical trial in patients with solid tumors or hematologic malignancies and disease progression on previous treatme...
Autores principales: | Luke, Jason J., Patel, Manish R., Blumenschein, George R., Hamilton, Erika, Chmielowski, Bartosz, Ulahannan, Susanna V., Connolly, Roisin M., Santa-Maria, Cesar A., Wang, Jie, Bahadur, Shakeela W., Weickhardt, Andrew, Asch, Adam S., Mallesara, Girish, Clingan, Philip, Dlugosz-Danecka, Monika, Tomaszewska-Kiecana, Monika, Pylypenko, Halyna, Hamad, Nada, Kindler, Hedy L., Sumrow, Bradley J., Kaminker, Patrick, Chen, Francine Z., Zhang, Xiaoyu, Shah, Kalpana, Smith, Douglas H., De Costa, Anushka, Li, Jonathan, Li, Hua, Sun, Jichao, Moore, Paul A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667103/ https://www.ncbi.nlm.nih.gov/pubmed/37857711 http://dx.doi.org/10.1038/s41591-023-02593-0 |
Ejemplares similares
-
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
por: Salles, Gilles, et al.
Publicado: (2021) -
The average relative dose intensity of R‐CHOP is an independent factor determining favorable overall survival in diffuse large B‐cell lymphoma patients
por: Długosz‐Danecka, Monika, et al.
Publicado: (2019) -
Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
por: Fontes, Magda S. C., et al.
Publicado: (2022) -
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
por: Berezhnoy, Alexey, et al.
Publicado: (2020) -
The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered
por: Borchmann, Peter, et al.
Publicado: (2018)